Bruno PAILLARD,Laurence DEL FRARI,Valérie BRUNNER,Adrian NEWMAN TANCREDI,Mark VARNEY
申请号：
US15310415
公开号：
US20170239231A1
申请日:
2015.07.09
申请国别(地区):
US
年份:
2017
代理人:
摘要：
The present invention relates to a method of treatment of movement disorders, comprising administering to a patient in need thereof an effective amount of befiradol, where in the administering step provides an average patient's maximum plasma concentration of befiradol below 15 ng/mL which occurs more than 4 hours post administration, said method minimizing side effects of dizziness and nausea. Sustained release pharmaceutical compositions that can be used according to this method are also described.
